EHA 2014 | Latest data with ONO-4059 and ibrutinib
Prof Simon Rule, Plymouth Hospital, Plymouth, UK, discusses data presented at EHA 2014 on the second-generation oral BTK inhibitor, ONO-4059. One study presented relates to CLL, the other to non-Hodgkin’s lymphoma (NHL). In both studies, ONO-4059 shows promising results which might allow it to compete with ibrutinib. Prof Rule also outlines the benefits seen with ibrutinib in several haematological cancers, and a presents a poster showing 2-year ibrutinib toxicity data.
Get great new content delivered to your inboxSign up